trending Market Intelligence /marketintelligence/en/news-insights/trending/_aoiklict2gnycgtpkr4ya2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Aslan Pharmaceuticals plans $86.3M IPO on Nasdaq

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Aslan Pharmaceuticals plans $86.3M IPO on Nasdaq

ASLAN Pharmaceuticals Ltd. plans to offer its American depositary shares, or ADSs, representing ordinary shares of about $86.3 million in an IPO on the Nasdaq Global Market.

The company has granted the underwriters an overallotment option to buy additional ADSs.

ASLAN plans to apply to list its ADSs on the Nasdaq Global Market under the symbol ASLN.

The clinical-stage oncology-focused biopharmaceutical company based in Singapore plans to use the net proceeds to fund its planned and ongoing clinical trials and manufacturing activities in preparation for a potential commercial launch.

The remaining net proceeds will be used to fund new and other ongoing research and development activities, working capital and other general corporate purposes.

Leerink Partners LLC and Piper Jaffray & Co. are acting as book-running managers and representatives of the underwriters, which include BTIG LLC, H.C. Wainwright & Co. LLC and CLSA Ltd.